Rectally absorbable form of L-dopa |
| What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered ... |
|
Rectally absorbable form of L-dopa |
| What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by ... |
|
Method to treat Parkinsons disease |
| I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which ... |
|
Method of using cytoprotective alcohols to treat neural disease and neural injury |
| The present invention is grounded in the surprising discovery that hexacosanol and analogues and ... |
|
Methods of treating Parkinson's disease using melanin |
| OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a ... |
|
Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds |
| OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-... |
|
L-DOPA ethyl ester to treat Parkinson's disease |
| OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ... |
|
Episomal vector systems and related methods |
| The present invention provides papilloma virus episomal vector systems and methods for papilloma ... |
|
Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker |
| What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ... |
|
Method of treatment of parkinson's disease |
| We claim: 1. A method of treatment of Parkinson's disease in a patient in need of such treatment, ... |
|
|
Substantially pure histidine-linked protein polymer conjugates
| Details |
Inventors: Lee, Seoju; McNemar, Charles;
Assignee: Enzon, Inc. (Piscataway, NJ)
Primary Examiner: Russel; Jeffrey E.
Assistant Examiner:
Attorney, Agent or Firm: Roberts & Mercanti, LLP
Substantially pure histidine-linked protein-polymer conjugates and processes for their preparation are disclosed. The processes include contacting a protein with an activated polymer under conditions sufficient to facilitate covalent attachment of at least a portion of the polymer strands on histidine residues of the protein and thereafter substantially separating the histidine-linked conjugates from the remaining reactants. |
|
DETAILED DESCRIPTION In one aspect, the present invention includes substantially pure protein-polymer conjugates. The conjugates include a protein, such as an alpha interferon, covalently conjugated to a polymer, such as a polyethylene glycol, at a histidine (His) residue of the protein. In the case of an alpha interferon, the histidine is preferably the histidine 34. Preferably, the alpha interferon is interferon . alpha. 2b and the conjugates contain about one polymer strand per alpha interferon molecule. Histidine-linked mono-polymer conjugates of other proteins, such as IL-10, are also included as part of the invention. Compositions containing the preferred mono-polymer His-linked conjugates may also contain minor amounts of other mono-PEG-protein species, if desired. In another embodiment of the invention, methods of preparing substantially pure protein-polymer conjugates are provided. In particular, the methods are directed to preparing the protein-histidine residue linked polymer-conjugates. The methods include forming a plurality of protein-polymer conjugate species or positional isomers by reacting a protein such as alpha interferon, with a sufficient amount of suitably activated polymer under conditions sufficient to facilitate covalent attachment of protein molecules to activated polymer strands and thereafter substantially isolating the conjugated species or positional isomers in which the His linkage between the protein and polymer is established from the remaining conjugate species. In one preferred aspect of this embodiment, the activated polymer is a benzotriazole carbonate-activated polymer. In an alternative aspect, the activated polymer is an oxycarbonyl-oxy-N-dicarboximide-activated polymer such as succinimidyl carbonate (SC-PEG). These activated polymers allow the artisan to form a reaction pool in which a substantial portion of the conjugates include the polymer strand covalently linked to a histidine residue on the alpha interferon rather than on a lysine residue or N-terminus
|
| Related patents |
|
|
Crosslinked polymer compositions and methods for their use
The present invention discloses a crosslinked polymer composition comprising a first synthetic polymer containing two or more nucleophilic groups, and a second synthetic ...
|
|
|
Conjugation of polypeptides
OF THE INVENTION It is the object of the invention to provide polypeptide conjugates with reduced allergenicity. As described above it is well-known according to prior ...
|
|
|
High molecular weight polymer-based prodrugs
OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the present invention contain hydrolyzable linkages between the polymer ...
|
|
|
Non-antigenic amine derived polymers and polymer conjugates
In one aspect of the invention, there are provided amine-based polymer intermediates having the formula: R--B (I) wherein (R) is a water-soluble, substantially non-...
|
|
|
Biodegradable high molecular weight polymeric linkers and their conjugates
The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from ...
|
|
|
Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
|
|
|
Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
|
|
|
Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
|
|
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising rectally administering to a patient a ...
|
|
|